



PRODUCT: **Olumiant®**

COMPANY: Eli Lilly and Company

THERAPEUTIC AREA & INDICATION:

JAK inhibitor for treatment of Rheumatoid Arthritis
in patients who fail to benefit from existing
TNF alpha inhibitor therapies

ABOUT THE PRODUCT

Baricitinib is a novel orally-administered Janus kinase (JAK) inhibitor developed for the treatment of patients with rheumatoid arthritis (RA). The unmet medical need remains high in rheumatology despite other available treatment options such as TNFi.

Innovative features of Baricitinib include:

- First JAK1/JAK2 inhibitor developed for RA. Pioneering Phase 3 programs in high unmet need diseases like atopic dermatitis, lupus, pediatric interferonopathies, alopecia areata and COVID-19 infection.
- Tablet specifically engineered to rock and facilitate grasping with fingers through its shape and coating. Bottle shape and cap engineered to provide ease of opening and to conform to an arthritic hand.